Wolfe Research Assumes Guardant Health at Outperform, Announces Price Target of $150

Benzinga Newsdesk www.benzinga.com Positive 50.7%

Neg 0% Neu 0% Pos 50.7%

Wolfe Research analyst Mike Polark assumes Guardant Health (NASDAQ:GH) with a Outperform rating and announces Price Target of $150.